US2020061044A1PendingUtilityA1
Phacetoperane for treating of attention deficit hyperactivity disorder
Est. expiryNov 29, 2031(~5.3 yrs left)· nominal 20-yr term from priority
A61P 25/20A61P 25/00A61K 31/4458A61K 31/445C07D 211/22Y02P20/55
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.
Claims
exact text as granted — not AI-modified1 . Alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, for use in the treatment of an attention deficit hyperactivity disorder (ADHD).
2 - 10 . (canceled)Join the waitlist — get patent alerts
Track US2020061044A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.